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Abstract
Osteoarthritis is one of the most com-
mon degenerative conditions affecting knee
joint. As our understanding in the disease
pathogenesis is evolving, so do the treat-
ment modalities. One of the postulated
mechanisms suggests the production of
inflammatory cytokines secondary to
repeated micro trauma than in turn lead to
cartilage damage overtime. Cartilage being
avascular structure has limited potential for
repair. Based on this, recent studies have
been focusing on stimulating cartilage-heal-
ing process by growth factors. This is where
platelet-rich plasma comes in to light.
Literature is showing promising results of
platelet-rich plasma in treating knee
osteoarthritis. In this review we have dis-
cussed the preparation, composition, classi-
fication, uses of platelet-rich plasma as well
as evidence for its efficacy and complica-
tions.
Introduction
Osteoarthritis is one of the most com-
mon diseases affecting the knee joint. It is a
chronic degenerative disorder that due to its
widespread prevalence is a major economic
burden on the healthcare system of a coun-
try.1 It is characterized by progressive
degradation in the articular cartilage, osteo-
phyte formation and subchondral sclerosis.2
Osteoarthritis is known to be in the top ten
causes of disability around the world. In the
United States, it is the second most common
cause of productive work time loss (after
low back pain being the first).3 And
although it can involve any joint, for the
purpose of this review we would be restrict-
ing ourselves to Osteoarthritis of the knee
only.
According to Rayegani et al.,4 approxi-
mately 11 percent of women and 7 percent
of men suffer from some degree of knee
osteoarthritis. It is hence a significant cause
of pain, loss of functionality and deteriorat-
ing quality of life in a major proportion of
the population. It is postulated that due to
the increase in life expectancy and the
increasing trend of obesity, we are likely to
see an increase in the incidence and hence
prevalence of Osteoarthritis in years to
come.1 It is therefore crucial for new treat-
ment modalities to come forth in order to
address this growing global burden. 
One of the proposed mechanisms of
development of knee osteoarthritis suggests
that repetitive mechanical injury leads to a
constant production of inflammatory
cytokines such as IL-1 and TNF-alpha,
which leads to significant cartilage damage
overtime.5 Cartilage being an avascular
structure has low potential for regeneration
and repair.6
Treatment of knee osteoarthritis is con-
fined to symptomatic relief with the aim of
reducing pain, joint stiffness and increasing
joint mobility. Weight loss and exercise are
recommended life style modifications.7-9
The use of walking aids is also sugested.5
Pharmacological therapy includes the use of
acetaminophen and non-steroidal anti-
inflammatory drugs.10 Intra articular treat-
ment with Hyaluronic acid, corticosteroids
and platelet-rich plasma (PRP) has also
come into limelight.
Recent studies have been focusing on
stimulating the intraarticular cartilage heal-
ing process via growth factors.2 This is
where Platelet-rich plasma has sparked
interest. It is believed that since PRP has
growth factors and plasma proteins, it will
be able to modulate anti-inflammatory sig-
nals and promote angiogenesis.4 Literature
review has shown promising results of PRP
therapy in patients with knee osteoarthritis.
It is being used as an alternative therapeutic
agent, given intraarticularly in the affected
knee. Studies show reduction in pain and
overall improvement in joint motion. PRP
has chondrogenic11,12 and anabolic differen-
tiating13,14 properties found in vitro (at cell
culture level) as well as in vivo in mice and
rabbits15 showing major role in regeneration
of osteoarthritic cartilage. 
What is platelet-rich plasma? 
Platelet-rich plasma (PRP) is defined as
“a sample of autologous blood with concen-
trations of platelets above baseline val-
ues”.16 Normal platelet counts in blood
ranges from 150,000 to 350,000 platelets
per microliter. However, PRP has counts
two or four times higher than this.17
Platelets contain a high number of
cytokines and growth factors which are
believed to be able to slow down the degen-
eration process and may even initiate chon-
drogenesis.18
Historically PRP was first used in den-
tal surgery to accelerate the healing of
implants and jaw reconstruction. Seeing as
it is a cheap and minimally invasive modal-
ity its use has been explored in a wide vari-
ety of medical fields such as neurosurgery,
ophthalmology, dermatology, otolaryngolo-
gy and orthopedic surgery.6
In recent years, the popularity of PRP in
sports medicine has grown exponentially.
The reason for this rapid development is its
removal from the list of banned perform-
ance enhancers in 2011 (It was previously
classified as such due to its growth factor
content) and its approval by the
International Olympic committee.19
Classification of platelet-rich
plasma
To increase standardization of PRP
reporting and to facilitate the interpretation
of various clinical studies, several classifi-
cation systems for PRP have been suggest-
ed. One of these was the Sports medicine
Platelet-rich Plasma Classification system
suggested by Mishra et al.20,21 and summa-
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rized in Table 1. According to this nomen-
clature, PRP preparations were divided into
4 categories based on platelet concentra-
tions, WBC content and activation status.
Type 1 and Type 2 consist of preparations
with WBCs increased over baseline. Type 1
does not include the addition of an exoge-
nous activator such as calcium or thrombin
whereas Type 2 does. Similarly Type 3 and
Type 4 have minimal WBCs, with Type 3
having no exogenous activator and Type 4
having an exogenous activator. Each sub-
type is then further subdivided into 2
groups; A and B with group A having more
than five times platelets over baseline and
group B having less than five times platelets
than baseline. Due to the development of a
double spin system, which allowed greater
concentration of platelets to be achieved
with little or no WBCs or RBCs, this classi-
fication was deemed insufficient by
Mautner et al. in their review published in
2015.21 In 2009, another classification was
published by Dohan et al.22 This classifica-
tion stratified PRP according to platelet
concentrations, leukocyte concentrations
and the presence of fibrin. Preparations
were divided into four groups  namely; P-
PRP (pure PRP), L-PRP (leukocyte and
PRP), P-PRF (pure platelet-rich fibrin) and,
L-PRF (leukocyte and platelet-rich fibrin).
However, this was again deemed insuffi-
cient by Mautner et al. due to its lack of
information on RBCs and WBCs along with
its limited application to nonoperative con-
ditions. The next classification was suggest-
ed by DeLong et al.23 in 2012. This was the
“PAW” classification system that looked at
platelet concentration (P), activation (A)
and WBCs (W). 
Accordingly, platelets were stratified
into four groups with P1 having baseline
platelet concentrations and p4 having
greater than 1.2 million platelets per milli-
liter. Activation was either exogenous or not
and WBCs were categorized as above or
below baseline. Since there was no informa-
tion on RBCs and the stratification of
WBCs was just above or below baselines,
Mautner et al.21 argued that this was an
understatement regarding their role in PRP
action. Mautner and collegues21 then pro-
posed their own classification system name-
ly the PLRA system. This has been summa-
rized in Table 2. It takes in to account the
concentration of platelets, WBCs, RBCs
and the addition of an activating agent. 
Preparation of platelet-rich plasma 
It is important to appreciate the fact that
different PRP formulations were used in
different studies. To date there is no stan-
dardized method of PRP preparation.
Studies vary in the initial amount of autolo-
gous blood used to prepare 4-5 mL of PRP
as well as the type of anticoagulant used and
the centrifugation rates in their PRP prepa-
ration. Such differences make it difficult to
objectively compare different studies with
one another.
The basic mechanism of creation of
PRP includes withdrawal of 35-40 mL4,24 of
the patient’s own peripheral blood. This
may be done by using an 18G needle to col-
lect blood from the patient’s upper limb
from the cubital vein. The next step
involves the addition of an appropriate anti-
coagulant such as acid citrate dextrose4,18,24
and then passing the blood through two
cycles of centrifugation. The first centrifu-
gation (done at 1600rpm for 15 minutes
according to Rayegani et al.4 and
Raeissadat et al.24) stratifies blood into three
strata. The basal layer called red layer, con-
sists of erythrocytes, the middle (white)
layer is filled with leukocytes; and the top
or yellow layer contains plasma, platelets
and growth factors. A second phase (done at
2800 rpm for 7 min)4,24 is used to concen-
trate platelet-rich and platelet poor plasma
components.25,26 The use of a manual cen-
trifuge, easily available in affordable prices
in most medical centers and hospitals, can
assure the availability of PRP injections to
higher number of patients. Multiple cost-
effective preparation methods mentioned in
literature which can be effectively utilized
in developing countries.27,28 Obtaining PRP
by automated methods is expensive and can
be prohibitive in resource constrained coun-
tries.29,30
Composition of platelet-rich
plasma
Platelets
Platelets are small anucleated cells
formed from megakaryocytes.31 The lifes-
pan of platelets is 5-9 days, after which they
are predominately cleared by Kupffer cells
and hepatocytes.32 Platelets can be thought
of as a modified version of smooth endo-
plasmic retinaculum, containing lysosomes,
mitochondria, ribosome,33 and most impor-
tantly granules. 
Three types of granules are found in
platelets, namely alpha, dense and lyso-
somes. Alpha granules consist of more than
300 different proteins.34 Dense granules are
few in number and contain serotonin, hista-
mine, calcium, pyrophosphate and different
phosphate compounds like ADP, ATP, and
GDP.35 Lysosomes play a role in clot lysis.36
Studies show that different proteins
from platelet secretion have major roles in
chemotaxis, angiogenesis, cell proliferation
                             Review
Table 1. Sports medicine platelet-rich plasma classification.
                            White Blood Cells               Activation                     Platelet concentration
Type 1                          Increased                                       No activation                        A=5X or >
                                                                                                                                               B= <5X
Type 2                          Increased                                       Activated                                A=5X or >
B= <5X
Type 3                                                                                    No activation                        A=5X or >
                                                                                                                                               B= <5X
Type 4                                                                                    Activated                                A=5X or >
                                                                                                                                               B= <5X
Table 2. PLRA classification system.
Classification                  Criteria
P: Platelets count                     _P                                                                                  _M
                                                     Volume Injected                                                        Cells/microlitter
L: Leukocyte contenta              >1%                                                                              +
                                                     <1%                                                                              -
R: Red Blood contentb             >1%                                                                              +
                                                     <1%                                                                              -
A: Activation                               Yes                                                                                +
                                                     NO                                                                                -
aIf white blood cells are present (+), the percentage of neutrophils should be reported. bThe method of exogenous activation should be
reported.
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and differentiation. Some proteins have
bactericidal and fungicidal properties and
other cause aggregation of macrophages,
mesenchymal stem cells and osteoblast
resulting in removal of dead tissues .This
accelerates wound healing.37
Growth factors 
As previously mentioned Platelet-rich
plasma comprises of tissue growth factors
and inflammatory mediators (IL-1 receptor
antagonist, IL-6, TNF, alpha-2-macroglobu-
lin) (Table 3).19,38-43 These serve to increase
angiogenesis, promote chondrogenesis and
increase epithelial cell, osteoblast and
fibroblast proliferation. They also stimulate
the production of collagen and hyaluronic
acid.19
Various techniques for preparation of
PRP and isolation and differentiation of
growth factors from PRP are being studied.
The following growth factors have been
isolated from PRP.44
Platelet alpha granule derived
They are: Platelet derived growth factor
(PDGF); Vascular endothelial growth factor
(VEGF); Transforming growth factor beta-1
(TGF-b1); Epidermal growth factor (EGF);
Basic fibroblast growth factor (bFGF);
Insulin-like growth factor-1 (IGF-1).
Plasma derived
They are: Hepatocyte growth factor
(HGF); Insuline like growth factor-1 (IGF-
1).
Leukocytes
Depending on the preparation technique
PRP may be leukocyte rich or leukocyte
poor. It is postulated that leukocytes pro-
duce metalloproteinases and free radicals
which are detrimental for the joint and
increase post injection pain.4,19 However, a
possible advantage may be restriction of
microbial growth around the injection site.19
Other researchers believe that the leukocyte
release of enzymes is crucial for the repair
process as well.4
Clinical use of platelet-rich plasma
Platelets were initially used in plastic
and maxillofacial surgeries in 1990s with
favorable results.45 Later on, the technique
gained recognition in its usage in different
orthopedic surgeries like in bone grafts,46 to
increase spinal fusion and fracture heal-
ing.47 PRP is recently widely used for treat-
ment of osteoarthritis as one of biological
therapies because of its simplicity in prepa-
ration and cheap availability with absence
of risk of immunological reaction or disease
transmission.
Studies to see effects of PRP therapy in
osteoarthritis have shown that it improves
anabolic capacity of chondrocytes. Huang
et al.48 and Kilian et al.49 demonstrated in
vitro that PRP is capable of induction of
mesenchymal proliferation. Work of Mishra
et al.11 showed that PRP increases fibroblast
proliferation in vitro. They also added that
PRP increase gene expression for chondro-
genic and osteogenic differentiation. In
vitro study, Nakagawa et al.50 demonstrated
increased chondrocytes proliferation and
synthesis of collagen.
Efficacy of platelet-rich plasma
in the treatment of knee
osteoarthritis according to previ-
ous research and trials 
We did a literature search of clinical tri-
als published in this arena. We included all
studies that were available in English script
and were accessible to us as full text articles
(Supplementary Table S1).
Multiple clinical trials divided the study
patients into two groups; one of them
received intraarticular PRP injections and
the other was a control group. The control
group was given HA injections or acetamin-
ophen. The dosage, number of injections
and time interval varied in each study.
Follow up was done till 6 months and in
some trials till 12 months.24,51
Evaluations were done using Knee
Injury and Osteoarthritis outcome (KOOS),
Western Ontario and McMaster
University’s Arthritis Index (WOMAC),
Visual Analogue Scale (VAS), International
Knee Documentation Committee (IKDC)
and SF-36 questionnaire and significant
improvement in their mean scores was seen
in the PRP group.4,18,24,51,52 Physical and
mental components in SF-36 questionnaire
also showed significant improvement in the
PRP group. In two trials, VAS score
improved significantly in both the
groups.18,53 When analyzed for osteoarthritis
grades, early osteoarthritis (grade II) groups
showed more improvement with PRP treat-
ment compared to the late osteoarthritis
groups.24,51,53 Pain improved significantly in
the PRP group compared to the control
group at follow up.4,18,51-54 
Recently different systemic reviews and
meta-analysis studies have been published
to determine the efficacy of PRP therapy in
comparison to other intra-articular therapies
for treating osteoarthritis.
In 2017, Shen et al.55 conducted a sys-
temic review and meta-analysis of fourteen
randomized control trials (RCTs) from 2011
to 2016. The control comprised of saline
placebo, HA, ozone and corticosteroids. A
total of 1423 patients were included by ran-
domly. PRP therapy group included 12 to 96
patients control group include 11 to 96
patients.  Average follow up was 12 weeks
to one year. Follow up assessment after one
year showed better outcome with PRP ther-
apy. Patient assessment was done using
WOMAC score. Limitations of this review
were high heterogeneity among studies,
blinding of participants not done reliably
and substantial placebo effect.
Laudt et al.56 published a study in 2015
for determination of efficacy of PRP intra
articular injection therapy. They included
ten trials. Outcomes were measured by
visual analog scale and numeric rating
scale. Scores were improved with PRP ther-
apy as compared to placebo or HA at 6
months follow up. Limitations included
small number of studies and domain-based
evaluation done for assessing risk of bias
rather than using a scale or checklist. 
Wang-Saegusa et al.57 studied 312
patients with knee osteoarthritis. Three
injections of plasma-rich plasma at 2-week
intervals were given. At 6 months, the
patients reported a significant improvement
                                                                                                                             Review
Table 3.  Effect of PRP derived growth factors on Chondrocytes (Cartilage).
Growth Factor                                              Effect on Chondrocytes
Platelet derived growth (PDGF)                                Enhances cellular proliferation and proteoglycan production38
Transforming growth factor-beta (TFG-β)             Stimulates extracellular matrix (type II collagen and proteoglycan),decreases catabolic activity 
                                                                                          of interlukin-1(IL-1) and matrix metalloproteinase(MMP)39,40 
Fibroblast growth factor-2 (FGF-2)                          Stimulates proliferation of chondrocytes41
Insulin like growth factor-1 (IGF-1)                         Increases synthesis of type II collagen and proteoglycan while reducing amount of type I collagen42,43
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in pain, stiffness and function.
In a prospective study of 100 consecu-
tive patients, affected by knee osteoarthritis,
were treated with PRP intra-articular injec-
tions (115 knees treated). Patients evaluated
before and at the end of the treatment, and
at 6 and 12 months follow-up. IKDC, objec-
tive and subjective, and EQ VAS were used
for clinical evaluation. A statistically signif-
icant improvement of all clinical scores was
obtained from the basal evaluation to the
end of the therapy and at 6-12 months fol-
low-up.58
More studies from china concluded that
PRP therapy can be among successful
options. 
Complications of platelet-rich
plasma injection
Post injection pain at the injection site is
the most common complain reported in lit-
erature. These can be prevented by main-
taining an aseptic environment during
preparation and during the time of injection.
Rayegani et al.4 also reports transient
knee stiffness and local pelvic pain and sen-
sation of swelling. These complaints sub-
side after acetaminophen use and are not an
indication to discontinue treatment. 
Dhollander et al.59 described a case of
hypertrophy of regenerated cartilage tissue,
treated with arthroscopic debridement.
Combination therapy with of
platelet-rich plasma and
hyaluronic acid
Abate et al.60 was the first to publish a
study in 2015 regarding combination thera-
py of knee osteoarthritis with both intraar-
ticular injections of hyaluronic acid and
PRP. In their study, they enrolled patients
with mild to moderate knee osteoarthritis
and stratified them into two groups. The
first group received weekly injections of 2
mL hyaluronic acid added with 2 mL PRP
for three weeks. While the second group
received 4-5 mL of PRP only. Baseline
evaluation was done using VAS, KOOS and
weekly NSAID consumption. Standard
Ultrasound of the knee was also done to
look for effusion and synovitis. This was
repeated at 1, 3 and 6 months. Intra group
comparisons showed statistically significant
improvement in both groups. However infra
group comparisons failed to demonstrate
any statistically significant differences.
Hence it was concluded in this study that
the combination regimen of Hyaluronic
acid and platelet-rich plasma (PRP) gave no
added advantage than PRP administered
alone but in higher volumes. It was postu-
lated in this study that hyaluronic acid has a
synergistic effect with PRP by improving
the activity of many molecules in PRP.
JFSD et al.54 conducted a randomized
control trial that compared hyaluronic acid,
platelet-rich plasma and the combination of
both in the treatment of mild and moderate
osteoarthritis of the knee in 105 patients.
The study had three groups of PRP, HA and
combined PRP and HA. The study found
that combining HA and PRP resulted in sig-
nificant decreases in pain (P=0.0001) and
functional limitation (P=0.0001) when
compared to the HA group at 1 year follow
up. Furthermore, physical function was sig-
nificantly increased at 1 and 3 months when
compared to the PRP group.
Conclusions  
Our review of Literature shows promis-
ing effects of PRP therapy for tissue healing
based on clinically and scientifically
described studies. Its effectiveness as a ther-
apeutic agent is still not proven however.
Recently RCTs have elaborated its applica-
tion in osteoarthritis patients but these stud-
ies often have a small sample size with short
term outcome. In general, clinical trials
have proved better outcomes as compared
to other modalities of intra articular injec-
tions in patients with knee osteoarthritis.
This is especially true for younger patients
with low degree of injury.
Scientific evidence from animal model
studies and in vitro studies is also well
described in literature. It shows that PRP
therapy increases anabolic capacity of
injured cartilage hence repairing the dam-
age.
PRP therapy can be considered as a
therapeutic agent to delay the onset of irre-
versible damage to the tissue and hence sur-
gical interventions in the form of prosthesis
placement. Recent literature supports the
use of PRP – with results substantiating as
the most effective conservative treatment
measure for Osteoarthritis. Further studies
with large sample size, are still needed to
determine the best formulation and process-
ing technique of PRP therapy and applica-
tion.
In our part of the world, where most
health expenses are met out of pocket by the
patient, PRP (by being endogenously pro-
duced) may help in reducing the total cost
of treatment. It may also achieve this by
decreasing the need for analgesics intake,
hospital visits and delaying surgical inter-
vention. We started this treatment in select
patients at our institute and are planning to
conduct further studies to form the basis for
further usage. 
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